X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
CGT9486 (bezuclastinib) is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation. It is being evaluated for the treatment of nonadvanced systemic mastocytosis.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
The net proceeds will be used for the clinical development of CGT9486 (bezuclastinib), which is a KIT mutant inhibitor for patients living with systemic mastocytosis and gastrointestinal stromal tumors.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $225.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 14, 2024
Details:
Cogent intends to fund the development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib), a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 06, 2023
Details:
The most advanced clinical program, CGT9486 (bezuclastinib), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
The net proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $172.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 16, 2022
Details:
Cogent intends to use the net proceeds from the offering for development, regulatory and commercial preparation activities relating to CGT9486 (bezuclastinib) and other product candidates, as well as for working capital and general corporate purposes.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2022
Details:
All patients treated with CGT9486 (bezuclastinib) achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
CGT9486 (bezuclastinib), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
New CGT9486 (bezuclastinib) nonclinical data demonstrated superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Details:
Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: CGT9486
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Bezuclastinib, is a selective tyrosine kinase inhibitor designed to potently inhibit KIT D816V mutation and KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, and Exon 17 mutations are found in patients with advanced gastrointestinal stromal tumors.
Lead Product(s): Bezuclastinib
Therapeutic Area: Immunology Product Name: CGT9486
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2021
Details:
Acquisition includes lead clinical-stage compound PLX9486, a potent and selective KIT D816V inhibitor.
Lead Product(s): Bezuclastinib,Sunitinib
Therapeutic Area: Oncology Product Name: PLX9486
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Unum Therapeutics
Deal Size: $104.4 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
